ImmunityBio experienced significant upward momentum driven by sustained commercial expansion of its flagship immunotherapy, Anktiva, alongside technical breakout activity across the biopharmaceutical market. Key sentiment drivers include growing institutional confidence in Anktiva’s commercial trajectory following robust quarterly revenue growth, as well as mounting market anticipation ahead of a pivotal regulatory milestone. The Food and Drug Administration is currently reviewing a supplemental Biologics License Application for Anktiva combined with BCG in non-muscle invasive bladder cancer, with a target action date set for early January 2027. This regulatory catalyst has anchored long-term bullish expectations among growth-focused…